Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $29.15 and traded as high as $29.81. Hims & Hers Health shares last traded at $29.3610, with a volume of 12,251,814 shares traded.
Hims & Hers Health News Summary
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: The Department of Health and Human Services reportedly said it would temporarily use “enforcement discretion” to allow compounding of six peptides. The decision could expand Hims & Hers’ treatment offerings and reduce near-term regulatory pressure on its compounded-medication business, supporting the stock’s move higher. HIMS stock jumps after HHS temporarily clears compounding of six peptides
- Positive Sentiment: The HHS action is being viewed as a potential relief for telehealth providers that rely on compounded therapies. However, the policy is temporary, so the longer-term commercial benefit remains dependent on future regulatory decisions. Hims & Hers jumped as HHS uses enforcement discretion to open peptide compounding
- Neutral Sentiment: Hims & Hers is seeking dismissal of a Federal Trade Commission and states’ data-privacy case. A successful dismissal could remove a legal risk, but the outcome is unresolved. Hims & Hers seeks dismissal of FTC and states’ data privacy case
- Negative Sentiment: Multiple law firms reiterated that investors have until November 2, 2026, to seek lead-plaintiff status in a securities class action covering purchases from August 4, 2025, through July 29, 2026. The case stems from allegations tied to the FTC’s complaint, including alleged business misconduct, privacy, and billing practices. These are allegations, not established findings, but the litigation creates reputational, financial, and management risks. HIMS class-action deadline alert
- Negative Sentiment: Investor commentary also highlights the possibility of a substantial further decline, underscoring continued volatility and uncertainty around HIMS’s legal exposure, regulatory outlook, and profitability. Can Hims & Hers stock fall 30%?
Wall Street Analyst Weigh In
HIMS has been the topic of a number of research reports. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Bank of America raised their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, TD Cowen upped their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $32.43.
View Our Latest Analysis on Hims & Hers Health
Hims & Hers Health Trading Up 5.2%
The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The business has a fifty day simple moving average of $29.15 and a 200 day simple moving average of $27.11. The stock has a market cap of $6.85 billion, a price-to-earnings ratio of -46.60 and a beta of 2.44.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The company had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same period last year, the firm earned $0.17 earnings per share. The business’s revenue was up 38.2% compared to the same quarter last year. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.
Insider Buying and Selling
In other Hims & Hers Health news, insider Soleil Boughton sold 3,461 shares of the company’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $29.06, for a total value of $100,576.66. Following the transaction, the insider directly owned 297,348 shares in the company, valued at approximately $8,640,932.88. This represents a 1.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer directly owned 456,660 shares in the company, valued at $12,964,577.40. This represents a 2.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 130,443 shares of company stock worth $3,731,426. 11.76% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Hims & Hers Health
A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. Versant Capital Management Inc lifted its stake in shares of Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after purchasing an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares during the last quarter. GK Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $37,000. Compass Financial Management LLC purchased a new stake in shares of Hims & Hers Health in the second quarter valued at $50,000. Finally, Bogart Wealth LLC grew its position in shares of Hims & Hers Health by 180.7% in the first quarter. Bogart Wealth LLC now owns 2,526 shares of the company’s stock valued at $52,000 after purchasing an additional 1,626 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.
About Hims & Hers Health
Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.
Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
